Trial Profile
Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2017
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemosiderosis
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 05 Sep 2017 New trial record